Introduction {#bju14368-sec-0001}
============

A key focus in evaluation of treatments is to have an accurate way of measuring outcomes. Survival and time to cancer progression are common primary outcomes in oncology. However, there is increased recognition of the importance of measuring what were previously regarded as softer outcomes, such as health‐related quality of life (HRQL) using patient‐reported outcome measures (PROMs) [1](#bju14368-bib-0001){ref-type="ref"}. The number of PROMs available has grown exponentially and now there are numerous questionnaires available for assessing a multitude of domains in patients with cancer [2](#bju14368-bib-0002){ref-type="ref"}. This makes it difficult to decide which PROM to use in each population. When deciding, there are a number of issues to consider: does the PROM measure what it is meant to be measuring (validity), does it do so the same way each time (reliability), and does it detect real differences or changes (sensitivity). Systematic reviews of studies that report on these measurement properties (also known as psychometric) are useful for selecting the best PROMs for a specific purpose [3](#bju14368-bib-0003){ref-type="ref"}. A critical appraisal checklist to improve the selection of health‐measurement instruments has been recommended: COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN). The checklist provides clear assessment criteria and standards, so that the methodological quality of studies that report and evaluate the psychometric properties of PROMs can be assessed as part of a review process [3](#bju14368-bib-0003){ref-type="ref"}, [4](#bju14368-bib-0004){ref-type="ref"}. This methodology is preferred over traditional evidence‐based reviews, as the focus is not the evaluation of data provided by, or outcomes of PROMs, but the methodological quality of studies that report the psychometric properties of PROMs.

Bladder cancer (BC) is the ninth most common cancer worldwide and one of the most expensive malignancies to manage [5](#bju14368-bib-0005){ref-type="ref"}, [6](#bju14368-bib-0006){ref-type="ref"}. Treatment of and morbidity from non‐muscle‐invasive BC (NMIBC) and muscle‐invasive BC (MIBC) markedly differ [7](#bju14368-bib-0007){ref-type="ref"}, [8](#bju14368-bib-0008){ref-type="ref"}, and contribute to differences in patient HRQL [9](#bju14368-bib-0009){ref-type="ref"}. Treatment choice will depend on the stage of the cancer, recommendations by clinicians, and patient preferences. This should be informed not only by survival rates but also HRQL outcomes. A review and meta‐analysis of HRQL outcomes after radical cystectomy, where a variety of generic, cancer and BC‐specific PROMs measuring HRQL were employed, found mostly low‐powered studies finding similarities in HRQL between different types of diversions [10](#bju14368-bib-0010){ref-type="ref"}. Comparisons with the general population showed not only poorer urinary and sexual functioning in patients after cystectomy, but also deficits in social interactions, physical activity, and emotional function. Although HRQL improved in the year after surgery, evidence was mixed about longer term outcomes [10](#bju14368-bib-0010){ref-type="ref"}. HRQL in patients with NMIBC has been less well researched, possibly leading to the impression that there are few differences between the HRQL of patients with NMIBC and the general population [8](#bju14368-bib-0008){ref-type="ref"}. However, a recent study developed a conceptual framework for patient‐reported outcomes (PROs) in NMIBC derived from the literature, patients, and clinicians. This identified concerns about symptoms, treatment side‐effects, functional problems, and experiences of care. Some of these were related to more contemporary treatments and were not included in current PROMs [11](#bju14368-bib-0011){ref-type="ref"}.

The heterogeneity of BC and its treatments make choosing a PROM to assess HRQL challenging [9](#bju14368-bib-0009){ref-type="ref"}. Accurate measurement of HRQL in BC can only be achieved if the PROM chosen is 'fit for purpose' (i.e. psychometrically sound) and applied to the correct population. If the PROMs used are not 'fit for purpose' or are inappropriate for the patient group being studied, optimum levels of useful and informative HRQL data will not be gained from research. At worst, the data reported may be misleading or unhelpful. To date, a systematic review has not been undertaken to establish the psychometric properties of PROMs used in BC. Here we undertake a systematic review, using the COSMIN criteria. This will assess the quality of studies that report the psychometric properties of PROMs used with people with BC, determine the psychometric quality of these PROMS and identify the most promising generic, cancer‐generic and BC‐specific PROMs.

Materials and Methods {#bju14368-sec-0002}
=====================

Methods were informed by the University of York, Centre for Reviews and Dissemination guidance for undertaking systematic reviews and were published on their international database of prospectively registered systematic reviews, PROSPERO (reference CRD42016051974). The COSMIN approach was employed [3](#bju14368-bib-0003){ref-type="ref"}, [4](#bju14368-bib-0004){ref-type="ref"}. Guidance can be found at the COSMIN website (<http://www.cosmin.nl/>). The checklist has been used in other systematic reviews of oncological HRQL instruments [12](#bju14368-bib-0012){ref-type="ref"}, [13](#bju14368-bib-0013){ref-type="ref"} and was suggested in a non‐systematic review of BC HRQL research as a way to evaluate PROMs [9](#bju14368-bib-0009){ref-type="ref"}. For the purposes of reporting, instruments/measures to record HRQL will be referred to as PROMs. All stages of the process following the original electronic search were undertaken by two of the research team (S.J.M., P.W.), working independently of each other and then comparing outcomes at each stage of the process. Disagreements were resolved by discussion.

Search Strategy {#bju14368-sec-0003}
---------------

An electronic search of databases was carried out to identify publications evaluating psychometric properties of PROMs used in BC research. Searches were run in MEDLINE, EMBASE (both via OvidSP), CINAHL, PsycINFO, PubMed, The Cochrane Library, and Web of Science. Terms were agreed by the research team, appropriately modified for each database and limited to English language articles published between January 1990 and Current. Specific publication types were excluded from the search strategy, such as editorials and case reports, as per the search protocol developed by Terwee et al. [14](#bju14368-bib-0014){ref-type="ref"}. A combination of Medical Subject Headings (MeSH) and free‐text terms was used. Three groups of terms were generated describing: (i) the population; (ii) questionnaires, surveys and PROMs; and (iii) psychometric properties. Terms within each group were combined with the Boolean operator 'AND'. Searches were run in November 2016, with an updated search in September 2017. The updated search included the names of PROMs found from the initial search. Reference lists of pertinent review articles identified in the literature search were checked for relevant articles, as was conference proceedings from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and International Society for Quality Of Life Research (ISOQOL) [14](#bju14368-bib-0014){ref-type="ref"}. See [Data S1](#bju14368-sup-0001){ref-type="supplementary-material"} for an example of one database search strategy.

Study Selection Criteria {#bju14368-sec-0004}
------------------------

Inclusion criteria were English language, original studies that assessed patients with BC using a questionnaire or PROM to measure HRQL, where the study was a validation study or evaluated one or more psychometric properties of the questionnaire or PROM. Excluded were studies where the patient cohort included individuals aged \<18 years, where patients had bladder problems but not BC, where patients were diagnosed with another cancer (not BC), where the PROM or questionnaire was administered by interview or by proxy, and where the PROM was a clinician‐assessed instrument. Review articles, meeting abstracts, interviews, conference abstracts, editorials, and commentaries were also excluded.

Pilot testing of these criteria was undertaken to check for consensus. Testing consisted of two exercises where the reviewers (S.J.M., P.W.) independently used the inclusion and exclusion criteria to select or reject a subsample of titles and abstracts (200 in total). Following the first exercise, results were compared and interpretation of the criteria was discussed. Discrepancies were resolved through discussion. Discussions focussed on the different types of urinary diversion that may be included in BC HRQL research. Consensus was reached following the second phase of pilot testing.

Full‐text papers were retrieved for titles and abstracts that either appeared to meet inclusion criteria, or where uncertainty existed. These papers were further scrutinised independently by both reviewers to identify the final list included in the review.

Data Extraction {#bju14368-sec-0005}
---------------

The following data were extracted from each paper: PROM(s) used, constructs measured, content of the PROM and number of items/domains, psychometric information, administration method, study setting, study population, number of patients, patient demographics, response rate, country, and language. Data required to complete the COSMIN checklist assessment were also extracted.

Appraising Methodological Quality {#bju14368-sec-0006}
---------------------------------

The 4‐point COSMIN checklist was used to evaluate the methodological quality of studies, this evaluation is important as low‐quality studies are considered to have a high risk of biased results. The checklist consists of nine measurement properties, each with their own quality criteria, which form three domains ('reliability', 'validity', 'responsiveness'). Three measurement properties are part of the reliability domain: 'internal consistency', 'reliability', and 'measurement error'. Five measurement properties comprise the validity domain: 'content validity', 'structural validity', 'hypothesis testing', 'cross‐cultural validity', and 'criterion validity'. Responsiveness is a separate domain. An explanation of what each of the measurement properties are and COSMIN standards for reporting each measurement property is provided in Table [1](#bju14368-tbl-0001){ref-type="table"}.

###### 

Description of the COSMIN checklist measurement properties and standards for reporting each measurement property

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Measurement property      What the measurement property is                                                                                                                                                                                                                                                                     COSMIN standards for reporting the measurement property
  ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Content validity          Does the questionnaire include items relevant to the underlying outcome (construct) of interest?\                                                                                                                                                                                                    Evidence should be presented of an assessment concerning item relevance and scope\
                            Does it include items covering the full scope of the outcome?\                                                                                                                                                                                                                                       Development and pilot work with experts, clinicians and patients is typically undertaken and reported
                            The validity is assessed by examining how the items for inclusion in the questionnaire were generated. In this instance, the construct is HRQL in bladder cancer patients                                                                                                                            

  Structural validity       Sometimes HRQL questionnaires comprise a number of 'scales' which represent different constructs of interest\                                                                                                                                                                                        Factor analysis should be reported for Classical Test Theory\
                            The items within a scale should be related to each other, all contributing in a different way to the overall scale score\                                                                                                                                                                            Rasch analysis should be reported for IRT\
                            Tests of structural validity include factor analysis and Item Response Theory (IRT)\                                                                                                                                                                                                                 If exploratory factor analysis is undertaken at least 50% of all PROM variance should be explained by the factors and if confirmatory factor analysis is undertaken, factors should match the defined PROM scales\
                            These tests assess how well items fit the scale (unidimensionality) and whether they should be excluded                                                                                                                                                                                              Rasch analysis should be described including estimations for parameters of the model

  Internal consistency      Internal consistency is closely related to structural validity in that all the items within a scale must tap into the same basic underlying construct\                                                                                                                                               Following initial Factor analysis to check scale unidimensionality, Cronbach\'s α ≥ 0.70 or KR‐20 should be reported\
                            It is measured is by looking at the correlation between the items within a scale and examining the correlation of each item to the overall scale score if that specific item was excluded\                                                                                                           Items within the same scale or domain should be moderately correlated with each other
                            Cronbach\'s α or Kuder--Richardson Formula 20 (KR‐20) are used                                                                                                                                                                                                                                       

  Reliability               For a questionnaire to be reliable it should result in the same or similar responses or scores every time, if the circumstances of the people completing the questionnaire remain the same\                                                                                                          Test--retest reliability should be calculated using ICC for continuous scores or κ for dichotomous, ordinal or nominal scores, evidence of at least two independent measurements, with an appropriate time interval during which the participants were stable should be reported
                            One way of measuring reliability is using a test--retest method (using κ or ICC for scale scores)\                                                                                                                                                                                                   
                            If the scale is reliable the scores will stay the same when the PROM is completed twice by patients whose health is stable                                                                                                                                                                           

  Measurement error         Checks if changes in PROM score are due to reasons other than genuine changes in the construct being measured (an error in the measurement)                                                                                                                                                          Standard Error of Measurement (SEM), Smallest Detectable Chance (SDC) or Limits of Agreement (LoA) should be calculated

  Hypothesis testing        A reliable and valid questionnaire will pick up differences between groups of patients who are known to be different in terms of the construct of interest. For example, a HRQL questionnaire should be able to detect the difference between those with/without disease (disease free survivors)\   Evidence should be presented that hypotheses were formulated a priori, with the direction of mean differences or relative magnitude of correlations stated
                            Questionnaire may be evaluated by testing the hypotheses                                                                                                                                                                                                                                             

  Criterion validity        Compares whether PROM scores are similar to the scores of other PROMs used to measure the same construct that is accepted in the field being studied (a 'gold standard' PROM)                                                                                                                        Evidence should be presented that the criterion used was an adequate 'gold standard' (in the case of PROMs, the full version of a short form measure)

  Responsiveness            Responsiveness (or sensitivity to change) measures if the PROM detects changes in scores over time that are due to the impact of treatments or interventions                                                                                                                                         Appropriate statistical methods should be used. Reporting statistical significance with *P* values is not encouraged\
                                                                                                                                                                                                                                                                                                                                 Tests should measure the change of the PROM scores, not of health status or magnitude of an event or intervention

  Cross‐cultural validity   Measures whether the performance of the questions on a translated or culturally adapted PROM are similar or comparable to the performance of the questions in the original version of the PROM                                                                                                       The process of translating the PROM should be adequately described. Factor analysis should have been performed and reported
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IRT, Item Response Theory; KR‐20, Kuder--Richardson Formula 20.
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Each eligible study was rated for measurement properties as 'excellent', 'good', 'fair' or 'poor'. Checklist criteria are used to assess how well studies report each measurement property and whether they adhere to the COSMIN standards, e.g., providing evidence of adequate sample size, a priori hypotheses or how missing values were managed. An overall score is determined by taking the lowest rating gained on any of the checklist criteria for the evaluated measurement property: 'the worst score counts' [4](#bju14368-bib-0004){ref-type="ref"}.

Reporting of Psychometric Results {#bju14368-sec-0007}
---------------------------------

The psychometric results reported in the studies were described and categorised into the nine COSMIN measurement properties. Quality criteria proposed by Terwee et al. [15](#bju14368-bib-0015){ref-type="ref"} for health‐status questionnaires was used to determine whether the results for each measurement property were 'positive', 'negative' or 'indeterminate'. An example of these criteria is that if a study reported a Cronbach\'s α of \<0.70 for a PROM, the internal consistency for that study would be considered a negative result.

Levels of Evidence Appraisal {#bju14368-sec-0008}
----------------------------

A levels‐of‐evidence appraisal was undertaken to determine the overall quality of each measurement property, established in the different studies. The appraisal produced a final rating for each PROM for each of the measurement properties. All available information was synthesised, combining the results of the different studies for each PROM. PROMs were rated based on COSMIN checklist scores (reflecting the methodological quality of the studies), reported psychometric evidence, and quality of the evidence (whether results were positive, negative or indeterminate), the consistency of results between studies, and level of evidence. The levels of evidence rating could be 'strong' (+++ or −−−), 'moderate' (++ or −−), 'limited' (+ or −), 'conflicting' (+/−), or 'unknown' (?). For example, if two studies reported a Cronbach\'s α of \<0.70 for a PROM, but had both scored 'Good' on the COSMIN checklist for internal consistency, the rating would be '−−−', meaning there is strong evidence (multiple studies of good methodological quality) for low levels of internal consistency. However, if there was one study reporting a Cronbach\'s α of \>0.70 which scored 'Good' on the COSMIN checklist, the rating of that PROM for internal consistency would be '++', meaning there is moderate evidence in a study of good methodological quality. When there are only studies of poor methodological quality, an unknown rating is given. Levels‐of‐evidence criteria are presented in Table [2](#bju14368-tbl-0002){ref-type="table"} [14](#bju14368-bib-0014){ref-type="ref"}.

###### 

Levels of evidence for the quality of the measurement properties for PROMs, taken from Terwee et al. [14](#bju14368-bib-0014){ref-type="ref"}

  Level         Rating[\*](#bju14368-note-0002){ref-type="fn"}   Criteria
  ------------- ------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  Strong        +++ or −−−                                       Consistent findings in multiple studies of good methodological quality OR in one study of excellent methodological quality
  Moderate      ++ or −−                                         Consistent findings in multiple studies of fair methodological quality OR in one study of good methodological quality
  Limited       \+ or −                                          One study of fair methodological quality
  Conflicting   +/−                                              Conflicting findings
  Unknown       ?                                                Only studies of poor methodological quality

\*Positive rating, '+'; Indeterminate rating, '?'; Negative rating, '−'.
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Results {#bju14368-sec-0009}
=======

The initial search produced 4663 results. After removal of duplicates and screening titles and abstracts, 280 full texts were agreed for further examination, of which 19 met the inclusion criteria. Three articles were included from hand‐searching the reference sections of review articles and one article was included as a result of the updated search (Fig. [1](#bju14368-fig-0001){ref-type="fig"}). No results were found from hand‐searching ISPOR or ISOQOL conference proceedings. Overall, 23 studies, reporting PROMs in 3568 patients, were evaluated using the COSMIN checklist. An overview of studies and PROMs are presented in Table [3](#bju14368-tbl-0003){ref-type="table"} [16](#bju14368-bib-0016){ref-type="ref"}, [17](#bju14368-bib-0017){ref-type="ref"}, [18](#bju14368-bib-0018){ref-type="ref"}, [19](#bju14368-bib-0019){ref-type="ref"}, [20](#bju14368-bib-0020){ref-type="ref"}, [21](#bju14368-bib-0021){ref-type="ref"}, [22](#bju14368-bib-0022){ref-type="ref"}, [23](#bju14368-bib-0023){ref-type="ref"}, [24](#bju14368-bib-0024){ref-type="ref"}, [25](#bju14368-bib-0025){ref-type="ref"}, [26](#bju14368-bib-0026){ref-type="ref"}, [27](#bju14368-bib-0027){ref-type="ref"}, [28](#bju14368-bib-0028){ref-type="ref"}, [29](#bju14368-bib-0029){ref-type="ref"}, [30](#bju14368-bib-0030){ref-type="ref"}, [31](#bju14368-bib-0031){ref-type="ref"}, [32](#bju14368-bib-0032){ref-type="ref"}, [33](#bju14368-bib-0033){ref-type="ref"}, [34](#bju14368-bib-0034){ref-type="ref"}, [35](#bju14368-bib-0035){ref-type="ref"}, [36](#bju14368-bib-0036){ref-type="ref"}, [37](#bju14368-bib-0037){ref-type="ref"}, [38](#bju14368-bib-0038){ref-type="ref"} and Table [4](#bju14368-tbl-0004){ref-type="table"} [35](#bju14368-bib-0035){ref-type="ref"}, [36](#bju14368-bib-0036){ref-type="ref"}, [37](#bju14368-bib-0037){ref-type="ref"}, [38](#bju14368-bib-0038){ref-type="ref"}, respectively.

![Flow chart showing identification and selection of eligible articles.](BJU-122-760-g001){#bju14368-fig-0001}

###### 

Overview of studies included in the review

  --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(a\) MIBC population                                                                                           
  [17](#bju14368-bib-0017){ref-type="ref"} Mak et al., 2016                                                       
  Setting                                                                                                         Postal study in USA using English language EQ‐5D‐5L (version not reported) and EORTC QLQ‐BLM30
  Cohort                                                                                                          Patients with non‐metastatic MIBC with radical cystectomy \>2 years disease free. 226 eligible, 177 returned questionnaires. 25% of 109 radical cystectomy patients (median age 73 years) and 22% of 64 trimodality therapy (median age 76 years), 100% female
  [18](#bju14368-bib-0018){ref-type="ref"} Liu et al., 2016                                                       
  Setting                                                                                                         Recruited from Department of Urology, West China Hospital. Completed Chinese language version of WHOQOL‐BREF
  Cohort                                                                                                          MIBC with ileal conduit diversion with a postoperative period of 1 month to 2 years, 188 questionnaires returned, 66% aged ≥60 years, 19% female
  [21](#bju14368-bib-0021){ref-type="ref"} Moncrief et al., 2017                                                  
  Setting                                                                                                         Postal study in USA using English language BCI and FACT‐VCI
  Cohort                                                                                                          64 patients with MIBC with ileal conduit diversion (median age 72 years) or neobladder (median age 63 years), 25% female
  [29](#bju14368-bib-0029){ref-type="ref"} Anderson et al., 2012                                                  
  Setting                                                                                                         Recruited from Vanderbilt University and University of Chicago, USA. Completed English language FACT‐VCI
  Cohort                                                                                                          190 patients with MIBC with radical cystectomy and urinary diversion, median ([sd]{.smallcaps}) age 67 (10) years, 39% female
  [30](#bju14368-bib-0030){ref-type="ref"} Cookson et al., 2003                                                   
  Setting                                                                                                         Postal study in USA using English language FACT‐VCI
  Cohort                                                                                                          40 patients with MIBC with ileal conduit or neobladder, mean (range) age 67.5 (42--87) years, 17% female
  [31](#bju14368-bib-0031){ref-type="ref"} Stenzelius et al., 2016                                                
  Setting                                                                                                         Recruited ≥1 year after surgery from Skåne University Hospital, Sweden. Completed Swedish language version of FACT‐VCI, which had been translated as part of the study
  Cohort                                                                                                          63 patients with MIBC with urinary diversion, mean ([sd]{.smallcaps}) age 69.8 (9.1) years, 18% female
  [32](#bju14368-bib-0032){ref-type="ref"} Siracusano et al., 2014                                                
  Setting                                                                                                         Recruited from five Italian University clinics. Completed Italian language IONB‐PRO
  Cohort                                                                                                          171 patients with MIBC with orthotopic neobladder, mean ([sd]{.smallcaps}) age 64.3 (9.4) years, 9% female
  [35](#bju14368-bib-0035){ref-type="ref"} Caffo et al., 1996                                                     
  Setting                                                                                                         Postal study in Italy using Italian language *ad hoc* PROM
  Cohort                                                                                                          59 patients with T2--T3 MIBC; 30 cystectomy \[median (range) age 71 (49--84) years, 13% female\] and 29 conservative treatment \[median (range) age 72 (40--86) years, 21% female\]
  [36](#bju14368-bib-0036){ref-type="ref"} Bjerre et al., 1995                                                    
  Setting                                                                                                         Postal study and recruitment from outpatient clinics in Denmark using Danish language *ad hoc* PROM
  Cohort                                                                                                          67 non‐malignant patients with MIBC with urinary diversion. Excluded from study if aged ≥80 years, median (range) age 68.2 (50.8--75.7) years, 0% female
  [37](#bju14368-bib-0037){ref-type="ref"} Hart et al., 1999                                                      
  Setting                                                                                                         Postal study in USA using English language *ad hoc* PROM
  Cohort                                                                                                          224 patients with MIBC with cystectomy and either ileal conduit \[mean (range) age 76.2 (58--91) years\], Koch pouch \[mean (range) age 70.6 (49--97) years\] or urethral diversion \[mean (range) age 67.3 (37--86) years\], 24% female
  [38](#bju14368-bib-0038){ref-type="ref"} Henningsohn et al., 2002                                               
  Setting                                                                                                         Postal study in Denmark using a Swedish to Danish translation of *ad hoc* PROM
  Cohort                                                                                                          89 patients with MIBC with urinary diversion (mean age 64 years) and a control group (mean age 65 years), 10% of controls and patients female
  \(b\) NMIBC population                                                                                          
  [19](#bju14368-bib-0019){ref-type="ref"} Blazeby et al., 2014                                                   
  Setting                                                                                                         Recruited from Bladder COX‐2 Inhibition Trial (BOXIT). Completed English language EORTC QLQ‐C30 and EORTC QLQ‐NMIBC24 before treatment in UK clinic at 2, 3, 6, and 12 months
  Cohort                                                                                                          433 patients with NMIBC; 74.6% high risk, Ta 167 (41%), T1 167 (41%), Tis 45 (11%), Ta/Tis 17 (4%) and T1/Tis 14 (3%). Mean ([sd]{.smallcaps}) age 66.7 (9.3) years, 21% female
  [20](#bju14368-bib-0020){ref-type="ref"} Wei et al., 2014                                                       
  Setting                                                                                                         Recruited from The People\'s Hospital of Guangxi Zhuang Autonomous Region, China. Completed Chinese language EORTC QLQ‐C30 before treatment and 6 weeks after treatment
  Cohort                                                                                                          106 patients with NMIBC, 33% high risk, 57% aged ≥60 years, 23% female
  [34](#bju14368-bib-0034){ref-type="ref"} Mogensen et al., 2016                                                  
  Setting                                                                                                         Postal study in Denmark 1 week after discharge using Danish language EORTC QLQ‐NMIBC24
  Cohort                                                                                                          121 patients with NMIBC; pTa 68 (56%), pT1a 7 (6%), carcinoma *in situ* 9 (7%), mean (range) age 71 (41--96) years, 31% female
  [33](#bju14368-bib-0033){ref-type="ref"} Abáigar‐Pedraza et al., 2016                                           
  Setting                                                                                                         Primary care in Spain using Spanish language CAVICAVENMI
  Cohort                                                                                                          180 patients with NMIBC, age and percentage of females not reported
  \(c\) All patients with BC                                                                                      
  [22](#bju14368-bib-0022){ref-type="ref"}, [23](#bju14368-bib-0023){ref-type="ref"} Gilbert et al., 2007; 2010   
  Setting                                                                                                         Postal study in USA using English language BCI
  Cohort                                                                                                          315 patients; Ta, Tis, T1 166 (53%), T2--T4 119 (38%), Unknown 30 (9%), median (range) age 69 (41--89) years, 18% female
  [24](#bju14368-bib-0024){ref-type="ref"} Heyes et al., 2016                                                     
  Setting                                                                                                         Postal and recruitment at hospitals, private clinics and support groups in Australia. Completed English language BCI
  Cohort                                                                                                          119 patients with NMIBC and MIBC, mean ([sd]{.smallcaps}) age 70.7 (9.6) years, 26% female
  [25](#bju14368-bib-0025){ref-type="ref"} Schmidt et al., 2014                                                   
  Setting                                                                                                         Multicentre prospective study using Spanish language BCI, which had been translated as part of the study
  Cohort                                                                                                          197 patients; Tx: 5 (2.5%), Ta: 58 (29.4%), Tis: 5 (2.5%), T1: 102 (51.8%), T2a: 16 (8.1%), T2b: 6 (3%), T3: 3 (1.5%), T4: 2 (1%), Missing: 11 (5.6%), mean ([sd]{.smallcaps}) age 69.3 (11) years, 13% female
  [26](#bju14368-bib-0026){ref-type="ref"} Li et al., 2016                                                        
  Setting                                                                                                         Recruited from First Hospital of China Medical University. Completed Chinese language FACT‐Bl
  Cohort                                                                                                          365 patients, Stage 1: 233 (64%), Stages 2 and 3: 127 (35%), age 18--55 years, 74 (20%); 56--65 years, 125 (34%); 66--75 years, 115 (32%); \>75 years, 51 (14%), 20% female
  [27](#bju14368-bib-0027){ref-type="ref"}, [28](#bju14368-bib-0028){ref-type="ref"} Matsuda et al., 2003; 2004   
  Setting                                                                                                         Postal survey of patients chosen from Isere registry and Tarn registry in France using French language FACT‐Bl
  Cohort                                                                                                          95 patients, 80% had a superficial tumour, pTa or pT1, and 20% survivors had pT2 or higher median (range) age 72 (33--99) years, 18% female
  [16](#bju14368-bib-0016){ref-type="ref"} Hever et al., 2015                                                     
  Setting                                                                                                         Recruited from three hospital‐based urology centres in Hungary. Completed Hungarian language EQ‐5D (version not reported), SF‐36, BCI and FACT‐Bl
  Cohort                                                                                                          151 patients, T1: 43 (28%), T2: 14 (9%), T3: 6 (4%), T4: 1 (1%), Ta: 57 (38%), Tis: 4 (3%), Tx: 4 (3%), missing data: 22 (14%), mean ([sd]{.smallcaps}) age 66.3 (9.6) years, 35% female
  --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Overview of the PROMs that were evaluated

                                                                Name of PROM                                                                                                                                                                                                                                                                Content
  ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Generic                                                       EQ‐5D                                                                                                                                                                                                                                                                       5 items: mobility, self‐care, usual activities, pain, anxiety and depression, plus a visual analogue scale
  SF‐36                                                         36 items overall, mental component scale and physical component scale                                                                                                                                                                                                       
  WHOQOL‐BREF                                                   26 items; one from each of the 24 facets of WHOQOL100 plus 2 items from quality of life and general health items. Scales were physical health, psychological health, social relationships, and environment                                                                  
  Cancer generic                                                EORTC QLQ‐C30                                                                                                                                                                                                                                                               30 items. 9 scales. Functional scales: physical, role, emotional, cognitive, social, and global health status/quality of life. Symptom scales/items: fatigue, pain, and nausea and vomiting. Single items: dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties
  Bladder cancer                                                BCI                                                                                                                                                                                                                                                                         36 items. 3 domains: urinary (14 items), bowel (10 items), and sexual (12 items). 6 subscales as each domain has a function and bother subscale
  FACT‐Bl                                                       13 items specific to bladder cancer plus 27 item FACT‐G that comprises 4 scales; functional, social/family and physical wellbeing scales (7 items), emotional wellbeing scale (6 items)                                                                                     
  MIBC                                                          FACT‐VCI                                                                                                                                                                                                                                                                    17 items specific to radical cystectomy patients, plus 27 item FACT‐G that comprises 4 scales; functional, social/family and physical wellbeing scales (7 items), emotional wellbeing scale (6 items)
  IONB‐PRO                                                      Relational, fatigue, and emotional scales. Analysis from research produced several other scales                                                                                                                                                                             
  EORTC QLQ‐BLM30                                               30 items. 6 scales: urinary symptoms/problems, urostomy problems, future perspective, bloating and flatulence, body image and sexuality, plus single item about catheter use                                                                                                
  Caffo et al. [35](#bju14368-bib-0035){ref-type="ref"}         Ad hoc PROM. 40 items for cystectomy version, 41 for conservative treatment version. Items about physical wellbeing, pain, bowel function, urinary function, sexual function, daily physical activities, relational and recreational activities, stoma, and general items   
  Bjerre et al. [36](#bju14368-bib-0036){ref-type="ref"}        Ad hoc PROM. 211 items including items about urine leakage, diarrhoea, and skin complications                                                                                                                                                                               
  Hart et al. [37](#bju14368-bib-0037){ref-type="ref"}          Ad hoc PROM. About 105 items on emotional distress, quality of life (global), sexual dissatisfaction, body image, urinary diversion problems, sexual function, physical symptomology, daily living activities                                                               
  Henningsohn et al. [38](#bju14368-bib-0038){ref-type="ref"}   Ad hoc PROM. 137 items for patients, 125 for controls about urinary symptoms, bowel, and sexual dysfunction                                                                                                                                                                 
  NMIBC                                                         EORTC QLQ‐NMIBC24                                                                                                                                                                                                                                                           24 items. 6 scales: urinary symptoms, malaise, future worries, bloating and flatulence, sexual function, male sexual problems, plus 5 single items; intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual enjoyment and female sexual problems
  CAVICAVENMI                                                   21 items. 5 scales: disease, self‐esteem and emotional status, working life, daily life, and sex life                                                                                                                                                                       
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We identified three generic PROMs (EuroQoL five Dimensions \[EQ‐5D\] [16](#bju14368-bib-0016){ref-type="ref"}, [17](#bju14368-bib-0017){ref-type="ref"}, 36‐item short‐form health survey \[SF‐36\] [16](#bju14368-bib-0016){ref-type="ref"}, World Health Organisation Quality of Life \[WHOQOL‐BREF\] [18](#bju14368-bib-0018){ref-type="ref"}), one cancer‐generic PROM (European Organisation for Research and Treatment of Cancer quality‐of‐life, 30 item core questionnaire \[EORTC QLQ‐C30\] [17](#bju14368-bib-0017){ref-type="ref"}, [19](#bju14368-bib-0019){ref-type="ref"}, [20](#bju14368-bib-0020){ref-type="ref"}), seven BC‐specific PROMs including two for all patients with BC (Bladder Cancer Index \[BCI\] [16](#bju14368-bib-0016){ref-type="ref"}, [21](#bju14368-bib-0021){ref-type="ref"}, [22](#bju14368-bib-0022){ref-type="ref"}, [23](#bju14368-bib-0023){ref-type="ref"}, [24](#bju14368-bib-0024){ref-type="ref"}, [25](#bju14368-bib-0025){ref-type="ref"}, Functional Assessment of Cancer Therapy‐Bladder \[FACT‐Bl\] [16](#bju14368-bib-0016){ref-type="ref"}, [26](#bju14368-bib-0026){ref-type="ref"}, [27](#bju14368-bib-0027){ref-type="ref"}, [28](#bju14368-bib-0028){ref-type="ref"}), three for MIBC (FACT Vanderbilt Cystectomy Index \[FACT‐VCI\] [21](#bju14368-bib-0021){ref-type="ref"}, [29](#bju14368-bib-0029){ref-type="ref"}, [30](#bju14368-bib-0030){ref-type="ref"}, [31](#bju14368-bib-0031){ref-type="ref"}, EORTC QLQ‐BLM30 [17](#bju14368-bib-0017){ref-type="ref"}, Ileal Orthotopic Neobladder PRO \[IONB‐PRO\] [32](#bju14368-bib-0032){ref-type="ref"}), and two for NMIBC (CAVICAVENMI [33](#bju14368-bib-0033){ref-type="ref"} and EORTC QLQ‐NMIBC24 [19](#bju14368-bib-0019){ref-type="ref"}, [34](#bju14368-bib-0034){ref-type="ref"}). Four ad hoc MIBC PROMs were identified, which were developed specifically for the reporting study [35](#bju14368-bib-0035){ref-type="ref"}, [36](#bju14368-bib-0036){ref-type="ref"}, [37](#bju14368-bib-0037){ref-type="ref"}, [38](#bju14368-bib-0038){ref-type="ref"}. The BCI was the most frequently evaluated PROM (six studies). None of the PROMs were evaluated for all nine COSMIN measurement properties.

Methodological Quality {#bju14368-sec-0010}
----------------------

Table [5](#bju14368-tbl-0005){ref-type="table"} presents COSMIN checklist scores, assessing methodological quality of studies that reported COSMIN measurement properties for PROMs. The most frequently reported properties were internal consistency (18 studies) and hypothesis testing (15 studies). Criterion validity was not reported in any study due to lack of a 'gold standard', according to the COSMIN definition. Studies reporting on the BCI and FACT‐VCI provided the most detail and these PROMs could be evaluated on the most COSMIN measurement properties (seven properties).

###### 

COSMIN Checklist scores evaluating methodological quality of each study per measurement property and PROM

                                             Measurement properties                                                
  ------------------------------------------ ------------------------ ------ ------ ------ ------ ------ -- ------ ------
  Generic                                    EQ‐5D                                                                 
  [16](#bju14368-bib-0016){ref-type="ref"}                                                        Fair             
  [17](#bju14368-bib-0017){ref-type="ref"}                                                        Fair             
  SF‐36                                                                                                            
  [16](#bju14368-bib-0016){ref-type="ref"}                                                        Fair             
  WHOQOL‐BREF                                                                                                      
  [18](#bju14368-bib-0018){ref-type="ref"}                                   Poor                                  
  Cancer generic                             EORTC QLQ‐C30                                                         
  [19](#bju14368-bib-0019){ref-type="ref"}                                                        Good      Good   
  [17](#bju14368-bib-0017){ref-type="ref"}                                                        Fair             
  [20](#bju14368-bib-0020){ref-type="ref"}                                                        Fair             
  Bladder Cancer                             BCI                                                                   
  [23](#bju14368-bib-0023){ref-type="ref"}                                                        Fair             
  [22](#bju14368-bib-0022){ref-type="ref"}   Excellent                Good   Good   Fair          Fair             
  [16](#bju14368-bib-0016){ref-type="ref"}                            Poor   Poor   Fair          Fair             Poor
  [24](#bju14368-bib-0024){ref-type="ref"}                                   Fair                 Fair             
  [25](#bju14368-bib-0025){ref-type="ref"}                                   Poor                 Fair      Fair   Poor
  [21](#bju14368-bib-0021){ref-type="ref"}                                                        Poor             
  FACT‐Bl                                                                                                          
  [16](#bju14368-bib-0016){ref-type="ref"}                                                        Fair             
  [26](#bju14368-bib-0026){ref-type="ref"}                                   Poor                                  
  [27](#bju14368-bib-0027){ref-type="ref"}                                   Poor                                  Poor
  [28](#bju14368-bib-0028){ref-type="ref"}                            Poor                                         
  MIBC                                       FACT‐VCI                                                              
  [29](#bju14368-bib-0029){ref-type="ref"}                            Good   Good   Fair          Poor      Fair   
  [30](#bju14368-bib-0030){ref-type="ref"}   Poor                            Poor   Fair          Fair             
  [31](#bju14368-bib-0031){ref-type="ref"}                                   Poor   Poor          Fair             Poor
  [21](#bju14368-bib-0021){ref-type="ref"}                                                        Poor             
  IONB‐PRO                                                                                                         
  [32](#bju14368-bib-0032){ref-type="ref"}   Excellent                Fair   Fair          Poor   Fair             
  EORTC QLQ‐BLM30                                                                                                  
  [17](#bju14368-bib-0017){ref-type="ref"}                                   Poor                 Fair             
  Untitled                                                                                                         
  [36](#bju14368-bib-0036){ref-type="ref"}   Excellent                Poor   Poor                                  
  [37](#bju14368-bib-0037){ref-type="ref"}                                   Poor                                  
  [38](#bju14368-bib-0038){ref-type="ref"}   Excellent                                                             Poor
  [35](#bju14368-bib-0035){ref-type="ref"}   Excellent                Poor   Poor                                  Poor
  NMIBC                                      EORTC QLQ‐NMIBC24                                                     
  [19](#bju14368-bib-0019){ref-type="ref"}                                   Poor                 Good      Good   
  [34](#bju14368-bib-0034){ref-type="ref"}                            Fair   Fair                 Fair             
  CAVICAVENMI                                                                                                      
  [33](#bju14368-bib-0033){ref-type="ref"}   Excellent                Good   Poor   Poor          Fair             
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The best performing property was content validity, with six of the seven reporting studies receiving a score of 'excellent'. None of the other properties were given this quality rating due to the COSMIN rule of 'worst score counts'. For example, any study not reporting quantity of missing data or how missing values were managed could not receive an excellent rating on any property that included missing values as part of the assessment. The property with the worst performance was cross‐cultural validity, where all six studies scored 'poor' because factor analysis was not undertaken or the sample size was inadequate.

Psychometric Properties {#bju14368-sec-0011}
-----------------------

An overview of the psychometric properties for all PROMs is presented in [Table S1](#bju14368-sup-0002){ref-type="supplementary-material"}. When reported, response rates were between 45% and 98%, although many studies did not report response rates or percentage of missing items. Internal consistency was usually presented as Cronbach\'s α, although one study reported an item‐biased method but did not present results [36](#bju14368-bib-0036){ref-type="ref"}. Cronbach\'s α for scales and domains were not always presented as expected. For example, a study evaluating the BCI combined the urinary, bowel and sexual function items and urinary, bowel and sexual bother items; creating two new scales for which Cronbach\'s α was calculated [24](#bju14368-bib-0024){ref-type="ref"} instead of reporting on the scales and domains defined in the original BCI validation work [22](#bju14368-bib-0022){ref-type="ref"}, [23](#bju14368-bib-0023){ref-type="ref"}. Test--retest reliability was the only type of reliability reported by studies; with many reporting Pearson\'s or Spearman\'s correlations. Intraclass correlation (ICC) or κ scores were less frequently reported when reporting test--retest reliability and some studies did not explicitly report the test carried out. Content validity was usually undertaken using a combination of literature searching, a working group of clinicians and patients, and cognitive or pilot testing of items. Structural validity was assessed by either exploratory or confirmatory factor analysis. Rasch analysis was less common (two studies [32](#bju14368-bib-0032){ref-type="ref"}, [36](#bju14368-bib-0036){ref-type="ref"}). Responsiveness was reported in four studies, with one study reporting effect sizes. Although aspects of hypothesis testing were presented in studies (internal relationships and correlations with other instruments) because many findings were not hypothesised a priori, these studies were considered 'indeterminate'.

Levels of Evidence {#bju14368-sec-0012}
------------------

Table [6](#bju14368-tbl-0006){ref-type="table"} presents the levels of evidence for PROMs. All PROMs had at least one negative or unknown rating for COSMIN measurement properties. Despite being the most evaluated PROM, the BCI was rated negative for the most measurement properties; with reliability and hypothesis testing both rated as moderate negative.

###### 

Overall levels of evidence per measurement property and PROM

  PROM                                                          Measurement properties                                    
  ------------------------------------------------------------- ------------------------ ---- ---- ---- --- ---- --- ---- ---
  Generic                                                                                                                 
  EQ‐5D                                                         0                        0    0    0    0   −−   0   0    0
  SF‐36                                                         0                        0    0    0    0   −    0   0    0
  WHOQOL‐BREF                                                   0                        0    ?    0    0   0    0   0    0
  Cancer generic                                                                                                          
  EORTC QLQ‐C30                                                 0                        0    0    0    0   ?    0   ++   0
  Bladder Cancer                                                                                                          
  BCI                                                           +++                      ?    ++   −−   0   −−   0   ?    ?
  FACT‐Bl                                                       0                        ?    ?    0    0   −    0   0    ?
  MIBC                                                                                                                    
  FACT‐VCI                                                      ?                        −−   ++   ++   0   ++   0   \+   ?
  IONB‐PRO                                                      +++                      \+   \+   0    ?   \+   0   0    0
  EORTC QLQ‐BLM30                                               0                        0    ?    0    0   \+   0   0    0
  Caffo et al. [35](#bju14368-bib-0035){ref-type="ref"}         +++                      ?    ?    0    0   0    0   0    ?
  Bjerre et al. [36](#bju14368-bib-0036){ref-type="ref"}        +++                      ?    ?    0    0   0    0   0    0
  Hart et al. [37](#bju14368-bib-0037){ref-type="ref"}          0                        0    ?    0    0   0    0   0    0
  Henningsohn et al. [38](#bju14368-bib-0038){ref-type="ref"}   +++                      0    0    0    0   0    0   0    ?
  NMIBC                                                                                                                   
  EORTC QLQ‐NMIBC24                                             0                        ?    \+   0    0   ++   0   −−   0
  CAVICAVENMI                                                   +++                      ++   ?    ?    0   \+   0   0    0

+++, strong evidence positive result; ++ or −−, moderate evidence positive/negative result; + or −, limited evidence positive/negative result; ?, unknown rating, due to poor methodological quality; 0, not assessed.
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Six PROMs received strong positive ratings for content validity. FACT‐VCI was rated as unknown because the Cookson et al. [30](#bju14368-bib-0030){ref-type="ref"} paper did not assess whether all items were relevant for the study population.

Structural validity was evaluated in eight PROMs. IONB‐PRO and CAVICAVENMI received positive ratings. FACT‐VCI received a moderate negative rating, as factors generated from the factor analysis of postoperative data did not explain \>50% of the variance [29](#bju14368-bib-0029){ref-type="ref"}. This study also presented factor analysis based on preoperative data, which was not considered appropriate as FACT‐VCI is designed for use with patients who have undergone cystectomy. Five PROMs were rated unknown as the COSMIN checklist deemed the studies reporting on these PROMs to be of poor methodological quality due to inadequate sample sizes.

Internal consistency was evaluated in eleven PROMs. The BCI and FACT‐VCI were rated moderate positive. Four PROMs and three ad hoc PROMs were rated unknown, as the reporting studies were deemed to be of poor methodological quality because factor analysis had not been performed or the sample size for the analysis was too small.

Three PROMs measured test--retest reliability. The BCI was rated moderate negative as some Pearson\'s *r* figures were \<0.80. CAVICAVENMI was rated unknown as the study scored poor on the COSMIN checklist for methodological quality [33](#bju14368-bib-0033){ref-type="ref"}. Small sample sizes accounted for poor COSMIN checklist scores.

The IONB‐PRO, the only PROM for which measurement error was reported, received an unknown rating as the study calculated the standard error measurement based on Cronbach\'s α [32](#bju14368-bib-0032){ref-type="ref"}.

In all, 10 PROMs were evaluated for hypothesis testing. The FACT‐VCI and EORTC QLQ‐NMIBC24, were rated moderate positive. The BCI, FACT‐Bl, EQ‐5D and SF‐36 received negative ratings as \<75% of the a priori hypotheses were met and correlations with related constructs were lower than with unrelated ones. EORTC QLQ‐C30 was rated unknown, as it was difficult to establish which constructs were similar between the PROM and comparator PROMs.

Responsiveness was evaluated in four PROMs. The BCI was rated unknown as effect sizes were reported rather than correlations or area‐under‐curve, as required by COSMIN. The EORTC QLQ‐NMIBC24 was moderate negative, as \<75% of the results were in accordance with the stated hypotheses.

Five PROMs were evaluated for cross‐cultural validity and received unknown ratings.

Discussion {#bju14368-sec-0013}
==========

The aim of the present review was to provide robust information on the psychometric properties of PROMs used with BC cohorts, to aid selection of the most appropriate PROMs for HRQL assessment. In all, 23 studies were identified that reported measurement properties of 15 PROMs used with patients with BC over the last 27 years. None of the reviewed studies that reported psychometric properties of PROMs met all COSMIN criteria standards for methodological quality. Only two measures are applicable to all BC‐specific groups. Therefore, clinicians and researchers will have to choose the 'best fit' to serve their assessment objective. This may result in using a combination of generic, cancer‐generic and BC‐specific PROMs that reach the highest COSMIN standards.

Three generic PROMs were identified in the review, all had limited psychometric properties reported in studies; the EQ‐5D, SF‐36, and WHOQOL‐BREF [16](#bju14368-bib-0016){ref-type="ref"}, [17](#bju14368-bib-0017){ref-type="ref"}, [18](#bju14368-bib-0018){ref-type="ref"}. All three generic PROMs are established internationally with multiple non‐BC studies contributing normative and psychometric properties data. Consequently, they are accepted as being valid, reliable, sensitive, and applicable to a wide range of health problems [39](#bju14368-bib-0039){ref-type="ref"}. However, they may lack sensitivity in measuring cancer and BC‐specific issues, which is where more specialised PROMs, have a part to play. If being used alongside other more specific PROMs, clinicians and researchers may want to consider the following as part of their decision‐making process: the scope of the generic PROM, the number of items included, ease of administration, and permissions and costs.

Cancer‐generic PROMs, such as the EORTC QLQ‐C30 and FACT -- General (FACT‐G), provide information about patient experiences of general symptoms, such as nausea, pain and fatigue, and the impact of cancer on a patient\'s daily life, emotional health, and relationships. They can be used to compare the HRQL of patients with BC with other cancer populations. Although used as a stand‐alone cancer‐generic PROM in BC research, FACT‐G was not evaluated separately in the present review due to its inclusion as part of the FACT‐Bl and FACT‐VCI.

As with generic PROMs, psychometric evaluation of the EORTC QLQ‐C30 was not the focal point of studies included in the present review and thus very few psychometric properties were reported. During EORTC QLQ‐C30 development, the PROM was psychometrically evaluated in a culturally diverse sample of patients with lung cancer [40](#bju14368-bib-0040){ref-type="ref"} and by 2008, EORTC published reference data for a variety of cancer groups (but not for patients with BC) [41](#bju14368-bib-0041){ref-type="ref"}. Despite this, EORTC QLQ‐C30 is used in BC HRQL research.

BC‐specific PROMs focus on commonly reported BC problems such as with urinary, bowel and sexual function. Findings reported using these more specific PROMs may inform BC treatment regimens, policy and patient support. In the main, BC‐specific PROMs have been developed more recently than their generic and cancer‐generic counterparts and therefore have not been as widely used in research. There were 11 BC‐specific PROMs reviewed, of variable quality. On choosing which PROM to use, consideration should be given to how well it performed in the COSMIN review and the population of patients with BC being assessed.

If the target population includes the entire BC spectrum, then the choice of BC‐specific PROM must have been designed for this purpose. Only two PROMs fit this brief, the BCI and FACT‐Bl. Our present review found more support for the BCI, as it was more frequently evaluated in research and scored more favourably using COSMIN. However, the BCI is not without flaw, as evidence has suggested it may be difficult to interpret in circumstances where function and bother scores are different for a domain, under which circumstances researchers must choose whether HRQL should be determined by symptoms (function) or importance of symptoms to the patient (bother) [42](#bju14368-bib-0042){ref-type="ref"}. Consequently, it was recommended that a generic or cancer‐generic PROM be administered alongside the BCI [42](#bju14368-bib-0042){ref-type="ref"}. In comparison, FACT‐Bl scored poorly on the COSMIN checklist for all reported properties. However, a recent overview paper of BC PROMs suggests that the FACT‐Bl performs better than indicated in the present review. The authors state each new Functional Assessment of Chronic Illness Therapy (FACIT) scale undergoes an assessment of test--retest reliability, responsiveness, and convergent and divergent validity with 50 patients [42](#bju14368-bib-0042){ref-type="ref"} (confirmed by personal correspondence with FACIT, by S.J.M. on 14/09/2017). These psychometric data are neither published nor available within the public domain, meaning a complete COSMIN assessment cannot be undertaken, and therefore recommendation for use is not possible.

Seven MIBC‐specific PROMs were reported. The FACT‐VCI was the most evaluated in studies and had the most positive COSMIN ratings. It is used in HRQL studies comparing types of diversion, but is unsuitable to use with conservative treatment patients. Comparatively, the EORTC QLQ‐BLM30 was assessed for two measurement properties only, but can compare radical and conservative treatment‐related HRQL. Although only evaluated by one study, the IONB‐PRO scored well using the COSMIN checklist and appears to be a viable tool to administer to MIBC patients with neobladders. Four studies reported psychometric properties for a number of unnamed, ad hoc PROMs [35](#bju14368-bib-0035){ref-type="ref"}, [36](#bju14368-bib-0036){ref-type="ref"}, [37](#bju14368-bib-0037){ref-type="ref"}, [38](#bju14368-bib-0038){ref-type="ref"}, with no traceable evidence of further use.

Two PROMs were identified that measure HRQL in patients with NMIBC; both performing well when assessed using COSMIN. Although the case could be made to use either the EORTC QLQ‐NMIBC24 or CAVICAVENMI in research, the EORTC QLQ‐NMIBC24 has been evaluated more in research and can be used alongside EORTC QLQ‐C30. However, should clinicians and researchers prefer to use a PROM that includes a combination of cancer‐generic and BC‐specific items that comprises fewer items, they may wish to use CAVICAVENMI over the EORTC QLQ‐BLM30 combined with EORTC QLQ‐C30. Findings are described in Table [7](#bju14368-tbl-0007){ref-type="table"}.

###### 

Summary of review findings

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bladder cancer population             Best performing PROM using COSMIN                                                                                          Further information                                                                                                                    Alternatives      Further information
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  All (or a variety of stages/grades)   BCI                                                                                                                        Suggested that BCI is used alongside generic and/or cancer‐generic PROMs as interpretation can be difficult                            FACT‐Bl           FACT‐Bl can be used to collect BC‐specific and cancer‐generic HRQL information, as the PROM includes FACT‐G

  MIBC                                  FACT‐VCI                                                                                                                   FACT‐VCI can be used to collect BC‐specific and cancer‐generic HRQL information, as the PROM includes FACT‐G\                          EORTC QLQ‐BLM30   EORTC QLQ‐BLM30 can be used to collect BC‐specific and cancer‐generic HRQL information, as the PROM can be used with EORTC QLQ‐C30\
                                                                                                                                                                   FACT‐VCI is only suitable to use with MIBC patients who have had a cystectomy                                                                            EORTC QLQ‐BLM30 is suitable to use with both cystectomy and conservative treatment patients

  IONB‐PRO                              IONB‐PRO is only suitable to use with patients who have a neobladder                                                                                                                                                                                                                

  NMIBC                                 Difficult to determine as CAVICAVENMI only evaluated in one study and both EORTC QLQ‐NMIBC24 and CAVICAVENMI scored well   EORTC QLQ‐NMIBC24 can be used to collect BC‐specific and cancer‐generic HRQL information, as the PROM can be used with EORTC QLQ‐C30   CAVICAVENMI       CAVICAVENMI incorporates both BC‐specific and cancer‐generic questions within fewer items than the combination of EORTC QLQ‐C30 and EORTC QLQ‐NMIBC24
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Strengths and Limitations {#bju14368-sec-0014}
-------------------------

Although a strength of the present research is that methodological quality was assessed using the robust COSMIN checklist, carrying out the appraisal provided challenges. Many studies were not written with COSMIN criteria in mind, meaning interpretation of which COSMIN measurement properties were being assessed was sometimes difficult. For example, Blazeby et al. [19](#bju14368-bib-0019){ref-type="ref"} employed multi‐trait scaling when evaluating the structural validity of the EORTC QLQ‐NMIBC24. Multi‐trait scaling is not referred to in the COSMIN guidance. Advice from COSMIN (S.J.M. personal communication with Terwee 08/05/2017) stated that this method was not appropriate to assess structural validity. The complexity of applying the checklist appears to be acknowledged by COSMIN as the checklist is under review [43](#bju14368-bib-0043){ref-type="ref"} and their website has a frequently asked question (FAQ) section, regarding which measurement properties should be assessed when terminology other than that used by COSMIN is reported. Studies that received a negative or unknown rating, published following the publication of the COSMIN guidance, may have received a more favourable COSMIN rating if their guidelines had been taken into account when reporting the psychometric properties of PROMs.

Recommendations {#bju14368-sec-0015}
---------------

The emergence of new questionnaires, currently published as conference abstracts only [44](#bju14368-bib-0044){ref-type="ref"} and the identification of the four ad hoc MIBC PROMs, indicate existing PROMs used in BC research may not be perceived as adequate by the research and clinical community. Compared with previous COSMIN reviews [13](#bju14368-bib-0013){ref-type="ref"}, [45](#bju14368-bib-0045){ref-type="ref"}, the present review identified fewer PROM‐validation studies reporting an array of psychometric data. Unlike in other cancer populations, the psychometric properties of generic and general cancer PROMs are less well understood in BC populations. There would be a benefit in pooling data from studies that have used generic, cancer‐generic and BC‐specific PROMs to facilitate the undertaking of a more detailed psychometric analysis. This would enable organisations such as the EORTC to determine reference values for patients with BC and provide research teams with more information when choosing PROM(s) for HRQL research.

Any future psychometric evaluation of generic, cancer‐generic and BC‐specific PROMs should be reported and published, ideally using the COSMIN guidelines, so that it can be determined how useful these PROMs are with their intended BC populations.

Future HRQL research should implement the recommendation from previous research that BC‐specific PROMs be used alongside cancer‐generic PROMs in order to gain comprehensive information. Furthermore, it is recommended that generic PROMs should also be administered alongside cancer‐generic and BC‐specific PROMs to provide a robust picture of HRQL.
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BCI

:   Bladder Cancer Index

COSMIN

:   COnsensus‐based Standards for the selection of health Measurement INstruments

EORTC QLQ‐BLM30

:   European Organisation for Research and Treatment of Cancer quality of life questionnaire ‐ Muscle‐Invasive Bladder Cancer module

EORTC QLQ‐C30

:   European Organisation for Research and Treatment of Cancer quality of life questionnaire -- 30‐item core

EORTC QLQ‐NMIBC24

:   European Organisation for Research and Treatment of Cancer quality of life questionnaire ‐ Non Muscle‐Invasive Bladder Cancer module

EQ‐5D

:   EuroQoL five Dimensions

FACIT

:   Functional Assessment of Chronic Illness Therapy

FACT‐(Bl)(G)(VCI)

:   Functional Assessment of Cancer Therapy -- (Bladder) (General) (Vanderbilt Cystectomy Index)

HRQL

:   health‐related quality of life

ICC

:   intraclass correlation

IONB‐PRO

:   Ileal Orthotopic Neobladder PRO

ISOQOL

:   International Society for Quality Of Life Research

ISPOR

:   International Society for Pharmacoeconomics and Outcomes Research

(MI)(NMI)BC

:   (muscle‐invasive) (non‐muscle‐invasive) bladder cancer

PRO(M)

:   patient‐reported outcome (measure)

SF‐36

:   36‐item short‐form health survey

WHOQOL‐BREF

:   World Health Organisation Quality of Life
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